Protalix BioTherapeutics (PLX) Misses Q4 EPS by 7c
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.33 +0.87%
EPS Growth %: +400.0%
Financial Fact:
NET LOSS FOR THE PERIOD: -7.29M
Today's EPS Names:
SFNC, CSBR, MAN, More
EPS Growth %: +400.0%
Financial Fact:
NET LOSS FOR THE PERIOD: -7.29M
Today's EPS Names:
SFNC, CSBR, MAN, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q4 EPS of ($0.22), $0.07 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $62.89 million versus the consensus estimate of $6.12 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citizens launches transportation coverage, names FedEx a top large-cap pick
- Karooooo Ltd. (KARO) Tops Q2 EPS by 76c
- Taiwan Semi (TSM) Tops Q2 EPS by 51c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
